Breaking Down the Enigma of Dry Eye
A look at the science behind the development of lifi tegrast, and
where it fi ts into the therapeutic puzzle.
ARVO 2015 meeting finds connections in innovative drug delivery, therapies
Cutting-edge progress also continues in retina, cornea, dry eye, gene-based science
RISC and Reward with Inhibitory RNAs
A new understanding of ribonucleic acid’s activity in cells may
lead to breakthroughs in ophthalmic treatment.
Delivering a Rocky Mountain ARVO
A rundown of the most interesting research in a variety of subspecialties presented at this year’s ARVO meeting.
The Secrets of Ocular Microbiomes
The placid ocular surface is actually teeming with life that might
hold the secret to treating ophthalmic disease.
A Stepwise Approach To Acute Dry Eye
How to approach the occasional situation in which this chronic condition suddenly becomes acute.
Quarterly Ora Newsletter - May 1, 2015
Customer Success Stories: Celebrating Your Big Wins in 2014-2015
Mitotech Announces Phase 2 Data Showing Positive Effect of SkQ1 in Patients with Dry Eye Syndrome
SkQ1 is the first mitochondria-targeted antioxidant to reach clinical phase of development for an ophthalmic indication
RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S.
U.S. joint venture with G-treeBNT (ReGenTree LLC) has retained Ora, Inc.